On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
BUSINESS
Nesp Biosame Priced at 62.8-69.2% of Originator
A key reimbursement policy panel agreed in March to price the so-called “biosame” version of the Nesp (darbepoetin alfa) renal anemia drug at 70% of the originator - just as that for biosimilars, as opposed to 50% for generics -…
To read the full story
Related Article
- Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
BUSINESS
- Chugai’s FoundationOne Approved as CDx for Larotrectinib in Japan
January 26, 2021
- Health Damages Linked to Kobayashi Kako Mix-Up Rise to 215
January 26, 2021
- Mitsubishi Tanabe Gets US Commercial Rights for Aquestive’s ALS Med
January 25, 2021
- Shipment Control Triggered for Bayer’s Stivarga on Overseas Delay
January 25, 2021
- Chugai, Taisho to Wind Up Edirol Sales Collaboration in April
January 25, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…